Disclaimer: Zepbound and Mounjaro are not currently available in Singapore. This article is for informational purposes only, and details may change over time.
At the moment, only Saxenda Daily Weight Loss Injection is available in Singapore.
Learn more about Saxenda here.
Introduction to Zepbound and Mounjaro
Eli Lilly's Zepbound and Mounjaro, incorporating tirzepatide, represent the latest advancements in weight management therapies. Zepbound, with FDA approval for long-term weight management, has demonstrated significant effectiveness in clinical trials, showcasing substantial weight loss among participants.
These injectable treatments, functioning similarly to existing medications like Ozempic and Wegovy, utilize a dual-action mechanism to target key hormones that regulate appetite and glucose levels, introducing a novel approach to weight management.
Benefits of Zepbound and Mounjaro
Designed for adults dealing with obesity or overweight conditions, especially those with additional health complications related to their weight, Zepbound and Mounjaro offer new hope.
Zepbound's Efficacy in Weight Management
Zepbound's role in weight management is substantiated by FDA approval and clinical trial outcomes. The SURMOUNT-1 trial revealed participants losing between 15% and 20% of their body weight over a span of 72 weeks.
Similarly, the SURMOUNT-2 trial indicated weight reductions of 13.4% to 15.7% within the same period at 10 mg and 15 mg doses, solidifying Zepbound's effectiveness in treating obesity and overweight issues.
Mounjaro's Utility in Diabetes and Weight Control
Though primarily recognized for diabetes management, Mounjaro's active ingredient, tirzepatide, also shows promise in weight management. By affecting the same hormonal pathways as Zepbound, Mounjaro facilitates a reduction in hunger and caloric intake, with ongoing research expected to further elucidate its impact on weight loss.
How Zepbound and Mounjaro Work in Weight Management
Zepbound and Mounjaro target the GLP-1 and GIP hormones, integral to appetite and glucose control. GLP-1 helps reduce appetite by slowing digestion and impacting the brain's satiety centers, while GIP, primarily involved in glucose regulation, also plays a role in weight management, potentially helping to mitigate common side effects like nausea associated with GLP-1 therapies.
Ideal Candidates for Zepbound and Mounjaro
Zepbound is particularly suited for individuals seeking long-term weight management solutions, especially those with obesity or overweight conditions accompanied by related health issues. Mounjaro, while initially aimed at diabetes management, similarly offers weight management benefits, making both treatments applicable to a wide audience in need of effective weight loss and glycemic control.
Comparing Zepbound, Mounjaro, Ozempic, and Wegovy
Zepbound and Mounjaro, both tirzepatide-based, are focused on weight management and diabetes control by targeting the GLP-1 and GIP receptors. Zepbound is tailored for weight management in individuals with obesity or overweight and related health conditions, while Mounjaro is primarily for type 2 diabetes management.
Ozempic and Wegovy, on the other hand, contain semaglutide and are aimed at GLP-1 receptors, with Ozempic used for type 2 diabetes and Wegovy for obesity, highlighting the distinct applications and target demographics for each medication.
Learn more about Ozempic here.
Learn more about Wegovy here.
Side Effects of Zepbound and Mounjaro
Zepbound is associated with side effects, most commonly gastrointestinal issues such as nausea and abdominal discomfort, which tend to decrease over time. While serious side effects are rare, it's crucial to monitor any adverse symptoms and consult a healthcare professional as needed.
